Top Markets
Coin of the day
Neoleukin Therapeutics, Inc. Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc.

NLTX
株式のランク #26679
Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused... Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused on developing immune-based treatments for conditions such as cancer, inflammatory responses, and autoimmune diseases, utilizing its proprietary protein design technology. The company's leading investigational therapy is NL-201, a novel protein meticulously crafted to emulate the therapeutic effects of the IL-2/IL-15 cytokines. This product candidate is intended for the management of various malignancies, including renal cell carcinoma and melanoma. The organization, founded in 2003, was previously known as Aquinox Pharmaceuticals, Inc. before officially changing its name to Neoleukin Therapeutics, Inc. in August 2019. Its operations are based out of Seattle, Washington.
株価
$3.49
最終同期: 2023-12-19
時価総額
$38.68M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Neoleukin Therapeutics, Inc. (NLTX)

カテゴリー

Neoleukin Therapeutics, Inc.(NLTX)の収益
Aug 2026 時点の収益 TTM: 0
Neoleukin Therapeutics, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Neoleukin Therapeutics, Inc. の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。